Skip to main content

Research Repository

Advanced Search

Fulvestrant for the treatment of advanced breast cancer

Blackburn, Sophie A.; Parks, Ruth M.; Cheung, Kwok-Leung

Fulvestrant for the treatment of advanced breast cancer Thumbnail


Authors

Sophie A. Blackburn

Ruth M. Parks



Abstract

Introduction: The current issues with endocrine therapy for treatment of advanced breast cancer include balance of efficacy of therapy versus tolerability as well as hormone resistance. The efficacy of fulvestrant, a selective oestrogen receptor degrader (SERD), has been demonstrated in hormone receptor positive patients previously untreated or treated with hormonal therapy.
Areas covered: This article discusses the journey of fulvestrant licensing, its efficacy in combination with other endocrine therapies and the future role it may have within breast cancer treatment.
Expert commentary: Within phase III trials, fulvestrant has demonstrated equivalent or improved clinical efficacy when compared with established endocrine agents. In the recent decade, fulvestrant has achieved licensing as a second line agent in non-operative advanced breast cancer at initially 250mg, increasing to 500mg. Presently, fulvestrant is licensed globally as first line endocrine management for advanced breast cancer in post-menopausal women. Early combination trials of fulvestrant and cyclin dependent kinase 4/6 inhibitors have demonstrated good clinical efficacy with improved progression free survival when compared to fulvestrant alone.

Journal Article Type Article
Acceptance Date May 2, 2018
Online Publication Date May 11, 2018
Publication Date May 15, 2018
Deposit Date Jun 28, 2018
Publicly Available Date May 12, 2019
Journal Expert Review of Anticancer Therapy
Print ISSN 1473-7140
Electronic ISSN 1473-7140
Publisher Taylor and Francis
Peer Reviewed Peer Reviewed
Volume 18
Issue 7
Pages 619-628
DOI https://doi.org/10.1080/14737140.2018.1473038
Keywords Fulvestrant, advanced breast cancer, endocrine therapy, pure anti-oestrogen
Public URL https://nottingham-repository.worktribe.com/output/932673
Publisher URL https://www.tandfonline.com/doi/abs/10.1080/14737140.2018.1473038
Additional Information This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Review of Anticancer Therapy on 11 May 2018, available online: http://www.tandfonline.com/10.1080/14737140.2018.1473038

Files





You might also like



Downloadable Citations